संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

genus lifesciences inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), homatropine methylbromide (unii: 68jrs2hc1c) (methylhomatropine - unii:p97ogj7l1l) - hydrocodone bitartrate and homatropine methylbromide is indicated for the symptomatic relief of cough in adult patients 18 years of age and older. limitations of use: - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4)]. - contraindicated in pediatric patients less than 6 years of age [see contraindications (4)]. - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)], reserve hydrocodone bitartrate and homatropine methylbromide for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. hydrocodone bitartrate and homatropine methylbromide is contraindicated for: - all pediatric patients younger than 6 years of age [see warnings and precautions (5.2, 5.3), use in specific populations (8.4)]. - significant respiratory depression [see warnings and precautions (5.2)]

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

genus pharmaceuticals limited - apomorphine hydrochloride - solution for inj/inf - 10 mg/ml

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

genus pharmaceuticals limited - apomorphine hydrochloride - solution for injection - 10 mg/ml

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

genus pharmaceuticals limited - apomorphine hydrochloride - solution for infusion - 5 mg/ml

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. betamethasone valerate foam, 0.12% is contraindicated in patients who are hypersensitive to betamethasone valerate, to other corticosteroids, or to any ingredient in this preparation.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine 50 mg in 1 g - lidocaine ointment 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. it is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidocaine ointment 5%.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

ingenus pharmaceuticals llc - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: 1.      the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2.      the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. 3.      the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in m

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

genus lifesciences inc. - phenytoin (unii: 6158tkw0c5) (phenytoin - unii:6158tkw0c5) - phenytoin 125 mg in 5 ml - phenytoin oral suspension, usp is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration and clinical pharmacology sections). phenytoin oral suspension, usp is contraindicated in those patients with a history of hypersensitivity to phenytoin, its inactive ingredients or other hydantoins. coadministration of phenytoin oral suspension, usp is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form. the free acid form of phenytoin is used in phenytoin oral suspension, usp. because there is approximately an 8% increase in drug content with the free acid form over that of the sodium salt, dosage

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - salicylic acid; mucopolysaccharide polysulfate - cutaneous gel - 20mg/1gram ; 2mg/1gram

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - salicylic acid; mucopolysaccharide polysulfate - cutaneous gel - 20mg/1gram ; 2mg/1gram